BioSpace

Biogen’s big lupus bet gets boost from new durability data for skin disease

All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study. Data from two Phase 3 studies of systemic lupus are expected by the end of the year.

By BioSpace

1 min read
Biogen’s big lupus bet gets boost from new durability data for skin disease
Biogen’s big lupus bet gets boost from new durability data for skin disease

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights